Healthcare Industry News: Questcor Pharmaceuticals
News Release - March 5, 2014
Revance to Add Angus C. Russell as Chairman to Its Board of DirectorsNEWARK, Calif., March 5, 2014 -- (Healthcare Sales & Marketing Network) -- Revance Therapeutics, Inc. (RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Angus C. Russell has been appointed as Chairman to its Board of Directors, effective immediately.
"Angus' impressive track record in the global biopharmaceutical industry will bring significant value to Revance and its Board of Directors," said Dan Browne, President and CEO of Revance. "With his extensive experience growing companies commercially, I am thrilled to have him as a partner as we continue to execute and build our business."
"Revance's innovative pipeline portfolio in the field of aesthetics and dermatology, coupled with experienced leadership team, make joining the Board an exciting opportunity for me," said Angus Russell. "I look forward to working with the Board and the team at Revance to help execute on a solid strategy to commercialize RT001 and RT002 for multiple aesthetic and therapeutic indications."
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc. (RVNC) is a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS(R), that enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.
Source: Revance Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.